Sandoz Group AG/Fr. SDZ
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Sandoz Group AG
Sandoz Group AG operates in the pharmaceutical industry and is primarily focused on the development, production, and marketing of generic pharmaceuticals and biosimilars. The company offers a wide range of products including antibiotics, dermatology treatments, and respiratory medicines. Sandoz initially began as an independent company and has a notable history as part of the larger Novartis group, from which it separated to re-establish its standalone position. Headquartered in Basel, Switzerland, Sandoz has a significant global presence in various key markets. The company's strategic positioning is bolstered by its extensive portfolio of generic and biosimilar medicines, allowing it to compete effectively within the cost-sensitive segments of the pharmaceutical market.
- Ticker
- Fr. SDZ
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 20,000
- Headquarters
- Basel, Switzerland
- Website
- www.sandoz.com
Sandoz Group AG Metrics
BasicAdvanced
CHF 35B
65.79
CHF 1.24
0.49
CHF 0.80
0.98%
Price and volume
Market cap
CHF 35B
Beta
0.49
52-week high
CHF 86.90
52-week low
CHF 52.54
Average daily volume
1.1M
Dividend rate
CHF 0.80
Financial strength
Current ratio
1.054
Quick ratio
0.624
Long term debt to equity
0.528
Total debt to equity
0.689
Dividend payout ratio (TTM)
68.89%
Interest coverage (TTM)
4.99%
Profitability
EBITDA (TTM)
1,319.571
Gross margin (TTM)
47.79%
Net profit margin (TTM)
5.53%
Operating margin (TTM)
9.27%
Effective tax rate (TTM)
23.19%
Revenue per employee (TTM)
CHF 488,410
Management effectiveness
Return on assets (TTM)
3.05%
Return on equity (TTM)
7.25%
Valuation
Price to earnings (TTM)
65.79
Price to revenue (TTM)
3.587
Price to book
3.93
Price to tangible book (TTM)
-45.12
Price to free cash flow (TTM)
43.352
Free cash flow yield (TTM)
2.31%
Free cash flow per share (TTM)
1.877
Dividend yield (TTM)
0.98%
Forward dividend yield
0.98%
Growth
Revenue change (TTM)
10.29%
Earnings per share change (TTM)
180.85%
3-year revenue growth (CAGR)
6.89%
3-year earnings per share growth (CAGR)
0.99%
What the Analysts think about Sandoz Group AG
Analyst ratings (Buy, Hold, Sell) for Sandoz Group AG stock.
Analyst projections of the future price of Sandoz Group AG stock.
Bulls say / Bears say
Biosimilars are taking a larger share of the business: they represented 34% of Q3 sales and continued to grow year on year. This gives Sandoz a stronger growth engine than its more price-exposed generics business. (Sandoz)
Sandoz raised its 2026 core EBITDA margin forecast to 23.0%–23.5%, signalling better expected profitability even as it lowered its sales outlook. The improved product mix and cost discipline could support earnings growth despite softer near-term revenue. (Sandoz)
The Bio100 plan targets mid-to-high single-digit annual sales growth through 2030 and more than a doubling of sales by 2035, with over 100 biosimilars in the portfolio by 2040. If Sandoz delivers, the strategy offers a sizeable longer-term growth runway. (Reuters)
Sandoz cut its 2026 sales-growth outlook to 5%–6% at constant currencies after Q3 results, citing short-term biosimilar supply constraints. That shows strong demand is not yet translating fully into sales and leaves less room for near-term growth. (Reuters)
Pricing remains a headwind: Sandoz expects a mid-single-digit decline in 2026, while it also reported tougher-than-expected market conditions in Germany. Continued price pressure could limit revenue growth even if volumes rise. (Sandoz)
The US generic-drug litigation settlements require substantial payments: Sandoz agreed to pay $400 million to states over seven years and $28.5 million to reseller plaintiffs. The company also said some individual opt-out claims remain unresolved, leaving further legal uncertainty. (Sandoz)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
Sandoz Group AG Financial Performance
Revenues and expenses
Sandoz Group AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Sandoz Group AG
AllEURUSD
Fund name | Fund size | Fr. SDZ weighting |
|---|---|---|
iShares STOXX Europe 600 Health Care€EXV4 | €729M | 2.10% |
iShares MSCI Europe Health Care Sector£ESIH | €940M | 2.09% |
iShares MSCI Europe Health Care Sector€ESIH | €940M | 2.09% |
iShares Edge MSCI Europe Momentum Factor£IEFM | €721M | 0.81% |
iShares MSCI Europe ex-UK€IEUX | €1.3B | 0.38% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.